Is Now the Time to Buy Aurora Cannabis (ACB)?

: ACB | Aurora Cannabis Inc. News, Ratings, and Charts

ACB – Aurora Cannabis reported its Q1 2020 financial results after the market closed yesterday, Thursday, November 14th, 2019.

Aurora Cannabis reported its Q1 2020 financial results after the market closed yesterday, Thursday, November 14th, 2019. Despite the fact that cannabis stocks had a terrible day because of Canopy Growth’s disappointing earnings release yesterday morning, shares of Aurora Cannabis continued to decline over 10% after hours. 

Aurora Cannabis posted a gross profit of $53.7 Million and 58% Cannabis Gross Margin. Aurora Cannabis generated Total Revenues of $75.6 Million which Included Medical and Consumer Cannabis Net Revenue of $60.5 Million and Wholesale Cannabis Net Revenues of $10.3 Million.

Aurora Cannabis saw a significant decline in revenues due to provincial ordering that slowed down considerably during the summer, as distributors sold through inventories. Also, the industry was impacted by the slow pace of retail store licensing. Canadian consumer cannabis revenues took the biggest hit declining 33% sequentially due to these factors.  

The Canadian government is responsible for causing a bottleneck in cannabis production, which in turn has led to many of the large-cap cannabis stocks, including Aurora Cannabis, to suffer.  This puts many of these cannabis companies in a very tough spot as they ramp up production, yet they are not able to sell their products due to a lack of sales channels. These companies need retail revenues to materialize.

Declines in revenues for two of the largest cannabis companies, Canopy Growth and Aurora Cannabis, on the same day was a double whammy, and their unimpressive results are being felt throughout the marijuna industry.  Just this week, the largest cannabis ETF, ETFMG Alternative Harvest ETF (NYSE:MJ), is trading 13% lower.

Investors want to see a clear path to profitability and growing revenues, which was essentially the opposite of what happened this quarter. However, there is some positive news and potential catalysts on the horizon for Aurora Cannabis: 

  • In yesterday’s report, Aurora Cannabis revealed that their cost per gram sold declined 25% sequentially to $0.85 per gram, which did deliver on the company’s promise to produce under 1 dollar per gram. 
  • They also reported that their market for medicinal marijuana is strong, as revenues increased 3% sequentially and their patient base grew 8% to 91,116 active patients. 
  • Aurora Cannabis ia looking to capitalize on then “cannabis 2.0” market which includes edibles and many different high margin products. 
  • And the rollout of more retail stores across Canada which should also help Aurora Cannabis grow revenues in the near term but this will all depend on how fast the government will allow new stores to open. 

Though the cannabis industry’s performance recently has been quite lackluster, we are still positive for the long-term.  When the Canadian government stops causing a bottleneck in the industry we believe Aurora Cannabis, and its competitors, will be able to grow revenues dramatically.  And we think Aurora Cannabis is positioning themselves to be an industry leader, not only in the Canadian market, but on the international front. 

(Disclosure: The author owns shares of Aurora Cannabis)

 

 


ACB shares were trading at $3.12 per share on Friday morning, down $0.17 (-5.17%). Year-to-date, ACB has declined -37.10%, versus a 26.25% rise in the benchmark S&P 500 index during the same period.


About the Author: Aaron Missere


Aaron is an experienced investor who is also the CEO of Departures Capital. His primary focus is on the cannabis industry. He also hosts a weekly show on YouTube about marijuana stocks. Learn more about Aaron’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ACBGet RatingGet RatingGet Rating
CGCGet RatingGet RatingGet Rating
MJGet RatingGet RatingGet Rating
CRONGet RatingGet RatingGet Rating
APHAGet RatingGet RatingGet Rating
TLRYGet RatingGet RatingGet Rating
CTSTGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Should Investors BEWARE this Market?

The S&P 500 (SPY) has been on a tear since November 1st when the Fed started to make their dovish tilt opening the door to future rate cuts. Unfortunately they keep not happening and start date keeps getting pushed further and further out. That has many wondering if stocks are getting ahead of themselves setting things up for a fall. Thus a good time to tune into what investment veteran Steve Reitmeister has to say about the market outlook along with his trading plan and top picks to stay ahead of the pack. Read on below for more...

Top 4 Tech Giants Poised for Explosive Growth

Fueled by the ever-growing demand for advanced technological solutions across various sectors and ongoing innovation, the tech industry has robust growth prospects. Thus, it could be wise to invest in top tech stocks Dropbox (DBX), TTM Technologies (TTMI), Lantronix (LTRX) and AstroNova (ALOT) for potential growth. Continue reading…

3 Top Rated Software Stocks to Streamline Your Investments

The software industry is thriving with soaring demand, presenting ample investment opportunities. So, fundamentally solid software stocks ServiceNow (NOW), Autodesk (ADSK), and Docebo (DCBO) might be ideal buys for promising returns. Read on...

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading...

Is the Bull Market Growing Tired?

On the one hand it is fun to celebrate the new highs for the S&P 500 (SPY) that came in this Tuesday. On the other hand...it doesn’t make a lot of sense calling into question the next moves for the stock market. Read on below to appreciate investment veteran, Steve Reitmeister’s, market outlook and top picks to outperform.

Read More Stories

More Aurora Cannabis Inc. (ACB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ACB News